International non-public fairness agency KKR is attempting to promote partial stake in JB Chemical compounds and Prescribed drugs. For this, KKR has launched a block take care of a base measurement of about $ 200 million. KKR is the promoter of this firm. One of many a number of sources related to the case advised Moneycontrol, “The block deal has been launched a while in the past and KKR plans to promote about 7 %. There may be additionally an choice to promote a further 3.5 % stake, which prices round $ 100 million.” In keeping with the newest alternate knowledge, the corporate managed by KKR is the TAU Investments Hollings PTE LTD, holds 53.66 % stake in JB chemical compounds. One other supply says, “The ground value is Rs 1,625 per share and Kotak Mahindra Capital, Jeffaries, IIFL Capital and Avends Capital are funding bankers engaged on this commerce.” The share of JB Chemical compounds and Prescribed drugs closed at Rs 1703.40 on the BSE on 26 March. The corporate’s market cap is Rs 26500 crore. The inventory has climbed 13 % within the final 2 weeks, whereas in 2025, 9 % has come down to date. Within the final 2 years, the share value has strengthened greater than 70 %. Earlier, KKR had mentioned with strategic suitors in addition to non-public fairness corporations to exit its total stake in JB chemical compounds, however the dialog couldn’t flip into the deal as a result of valuations being mismatched. In July 2020, KKR agreed to buy about 54 % stake in JB chemical compounds for about Rs 3,100 crore. Within the December quarter, the revenue of Rs 156 crore rupees was recorded at Rs 913.51 crore on the standalone foundation within the October-December 2024 quarter. The web revenue was Rs 156.39 crore and Earnings was Rs 10 crore per share. In FY 2024, the corporate’s standalone foundation was recorded at Rs 3,298.64 crore, web revenue of Rs 543.36 crore and Earnings per share was Rs 35 crore.
